Data Dictionary: Pancreatic cancer - DPCA

Go back to Dutch Institute for Clinical Auditing Databases (DICA) (The Netherlands) page.

This is a summary of the variables available in the database. You can download the complete data dictionary here: Click here to learn more.

Table 1: Patient Demographics and Identification.

Variables	Description
Zorginstelling	Healthcare Institution
Uniek Patiëntnummer	Unique Patient Number
Burger Service Nummer	Social Security Number
Geslachtsnaam	Surname
Geboortedatum	Date of Birth
Geslacht	Gender
Land (Woonadres)	Country (Country of Residence)
Postcode	Postal Code
Datum overlijden (indien van toepassing)	Date of Death (if applicable)

Table 2: Comorbidities.

Variables	Description
Comorbiditeiten	Comorbidities, with options to add a new record or update based on changes or previous registrations

Table 3: Medical Procedures.

Variables	Description
Verrichtingen	Procedures, where multiple procedures per patient can be registered if applicable

Table 4: COVID-19 Module.

Variables	Description
Deze generieke COVID-19 module	A generic COVID-19 module added due to the impact of the coronavirus crisis on the quality of care, allowing for the better interpretation of indicators during this period

Table 5: Pathology Variables through PALGA.

Variables	Description
In het kader van de PALGA-koppeling worden pathologie variabelen	Pathology variables automatically structured and included in the registration via the PALGA-pathology module, requiring no additional data

Table 6: Patient Identification and Treatment Timeline.

Variables
Treatment start date
Reason for registration
Hospital patient number

Table 7: Patient Physical and Performance Metrics.

Variables
Height in cm
Preoperative weight in kg
Weight loss in kg and period in weeks
ECOG performance status (Eastern Cooperative Oncology Group)

Table 8: Laboratory Biomarkers.

Variables
Bilirubine in µmol/l
Hemoglobine in mmol/l
Albumine in g/l
IgG4 in g/l
Carcinoembryonic antigen (CEA) in µg/l
CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery)

Table 9: Imaging and Diagnostic Procedures.

Variables
CT, MRI, or MRCP performed
Date of the last preoperative imaging
Presence of a tumor in the pancreas or periampullary on CT or MRI
Cystic features suggestive of malignancy
Involvement of vessels and other structures on imaging

Table 10: Histology and Cytology.

Variables
Preoperative PA number
Method and date of obtaining the first positive cytology or histology
Histological and cytological diagnoses

Table 11: Multidisciplinary Team Consultations and Decisions.

Variables
Date of the last MDT (Multidisciplinary Team) discussion before treatment
Working diagnosis and eligibility for surgical exploration

Table 12: Treatment and Surgery Details.

Variables
Neo-adjuvant/induction treatment type and start date
Operative details including ASA score, type of resection, and operative complications
Postoperative pathology including tumor origin, size, and grade

Table 13: Postoperative Management and Follow-Up.

Variables
Palliative treatments including chemotherapy and radiotherapy
Date of discharge and any readmissions within 30 days
Adjuvant therapy details and participation in oncological trials

Table 14: SARS-CoV-2 Suspected or Confirmed Infection.

Variables
Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission.
Date of the first suspicion of SARS-CoV-2 infection.
Date of the first specific test for SARS-CoV-2 infection.
Date of the first positive laboratory test for SARS-CoV-2.
Final status regarding SARS-CoV-2 infection.

Table 15: Preoperative and Postoperative COVID-19 Testing.

Variables
Number of preoperative RT-PCR tests and the date of the first test.
Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
Number of postoperative RT-PCR tests and the date of the first test.
Date of the first postoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
Definitive preoperative and postoperative COVID-19 status.

Table 16: Patient Characteristics.

Variables
Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste).
Patient's smoking status and pack-years.
Patient's height (in cm) and weight (in kg) at admission.

Table 17: Surgical and Intensive Care Considerations.

Variables
Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events).
Impact on neoadjuvant treatment and changes in treatment plans or schedules.
Impact on surgical approach (laparoscopic, robotic, open) due to COVID-19.
Postoperative complaints consistent with COVID-19 and the number of days post-surgery they began.

Table 18:ICU Admission Related to COVID-19.

Variables
Presence and type of ICU admission related to COVID-19.
Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO).
ICU admission and discharge dates and durations.
Destination after ICU discharge.

Table 19: Sample Information.

Variables
Date of tissue arrival at laboratory
Pathology laboratory
Pathology number (TJJ-CCCCCC)
Protocol
Sample number

Table 20:Diagnostic Details.

Variables
Is cytology or histology obtained during the diagnostic process?
Most likely origin of the tumor
Histological diagnosis?

Table 21: Tumor Characteristics.

Variables
Largest tumor diameter in cm
Smallest margin in cm (radicality)
Tumor differentiation grade
Neuroendocrine tumor differentiation grade
pT-stage pancreatic carcinoma according to TNM8
Papil of Vater carcinoma according to TNM8
Distal cholangiocarcinoma according to TNM8
Duodenum carcinoma according to TNM8 small intestine

Table 22:Lymph Node and Metastasis Information.

Variables
Number of lymph nodes found
Number of tumor-positive lymph nodes found
Distant metastases?

Table 23:Response to Treatment.

Variables
Pathological response after neoadjuvant therapy with Histological Tumor Regression Grading (HTRG)